MedTrace Logo

Efficacy of Hepatitis B Vaccine Boosters Among Neonatally Vaccinated Children in Chongqing

NCT03867643 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2022-03-10

No results posted yet for this study

Summary

Worldwide, hepatitis B virus (HBV) infection is a major cause of acute hepatitis, and chronic infection with HBV often leads to chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. So far, the most effective way to prevent HBV infection in susceptible population is to inject hepatitis B vaccine. However, long-term protection against hepatitis B virus (HBV) after vaccination remains widely debated. This study aims to carry out a comprehensive study to evaluate the efficacy of hepatitis B vaccine booster from the aspect of humoral and cellular immunity in neonatally vaccinated children in Chongqing.

Conditions

  • Hepatitis B Vaccine Adverse Reaction

Interventions

BIOLOGICAL

hepatitis B vaccine(HepB)

Children with anti-HBs at a low level (\<10mIU/mL and \[10,100) mIU/mL) were received a dose of hepatitis B vaccine booster after informed consent.

Sponsors & Collaborators

  • Children's Hospital of Chongqing Medical University

    lead OTHER

Principal Investigators

  • Yao Zhao, postdoctor · Chongqing Children's Hospital of Chongqing Medical University

Eligibility

Min Age
1 Year
Max Age
15 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-09
Primary Completion
2021-09-09
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03867643 on ClinicalTrials.gov